Abstracts tagged "Disease Activity"

Abstract Number: 0065 • ACR Convergence 2021
Altered Expression of Several miRNAs in Axial Spondyloarthritis Patients with High Disease Activity
Jiri Baloun¹, Kristyna Bubova¹, Aneta Pekacova¹, Monika Gregova², Sarka Forejtova¹, Jana Horinkova¹, Michal Tomcik³, Jindriska Gatterova¹, Jiri Vencovsky¹, Karel Pavelka³ and Ladislav Senolt³, ¹Institute of Rheumatology, Prague, Czech Republic, ²Rheumatology Institute Prague, Prague, Czech Republic, ³Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic
Background/Purpose: Recent studies have shown that microRNAs (miRNAs) play a role in various disorders, including immune mediated inflammatory diseases. Therefore, we studied relationship between miRNA…
Abstract Number: 0359 • ACR Convergence 2021
Patient Journey with Axial Spondyloarthritis: Critical Issues from the Patient Perspective. Results from the European Map of Axial Spondyloarthritis (EMAS)
Marco Garrido-Cumbrera¹, Denis Poddubnyy², Christine Bundy³, Laura Christen⁴, Raj Mahapatra⁵, Souzi Makri⁶, Carlos Jesús Delgado-Domínguez⁷, Sergio Sanz-Gomez⁷, Pedro Plazuelo-Ramos⁸ and Victoria Navarro-Compán⁹, ¹Health & Territory Research (HTR), University of Seville, Sevilla, Spain, ²Department of Rheumatology, Charité – Universitätsmedizin, Berlin, Germany, ³Cardiff University, Cardiff, Wales, United Kingdom, ⁴Novartis Pharma AG, Basel, Switzerland, ⁵Axial Spondyloarthritis International Federation (ASIF), London, United Kingdom, ⁶Cyprus League Against Rheumatism (CYPLAR), Limassol, Cyprus, ⁷Health & Territory Research (HTR), Universidad de Sevilla, Seville, Spain, ⁸Spanish Federation of Spondyloarthritis Associations (CEADE), Madrid, Spain, ⁹Rheumatology service, Hospital Universitario La Paz-IdiPaz, Madrid, Spain
Background/Purpose: The journey of axial spondyloarthritis (axSpA) for most patients is slow and arduous. The goal of this analysis is to assess the journey to…
Abstract Number: 0757 • ACR Convergence 2021
Different Versions of the Patient Global Question in Rheumatoid Arthritis – Does It Really Matter? – Results of a Multi-center Observational Study
Paul Studenic¹, Aliaksandra Baranskaya², Stanley Cohen³, Nancy Shadick⁴, Christine Iannaccone⁵, Maria Dahl Mjaavatten⁶, Elisabeth Lie⁷, Tore Kvien⁸, Josef Smolen⁹, Daniel Aletaha¹⁰ and Helga Radner⁹, ¹Karolinska Institute; & Medical University of Vienna, Stockholm, Sweden, ²Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom, ³Metroplex Clinical Research Center, Dallas, TX, ⁴Brigham & Women's Hospital, Boston, MA, ⁵Brigham and Women’s Hospital, Topsfield, MA, ⁶Diakonhjemmet Hospital, Haslum, Norway, ⁷Diakonhjemmet Hospital, Oslo, Nepal, ⁸Diakonhjemmet Hospital, Oslo, Norway, ⁹Medical University of Vienna, Vienna, Austria, ¹⁰Medical University Vienna, Vienna, Austria
Background/Purpose: The patient global assessment (PGA), typically assessed as 'Considering all of the ways your arthritis has affected you, how do you feel your arthritis…
Abstract Number: 0877 • ACR Convergence 2021
Association of HCQ Blood Levels with Type 1 and 2 SLE Activity
Kai Sun¹, Amanda Eudy², Jennifer Rogers¹, Lisa Criscione-Schreiber¹, Rebecca Sadun², Jayanth Doss², Kelley Brady³, Roberta Alexander³, John Conklin³, Rory Bloch³ and Megan Clowse⁴, ¹Duke University School of Medicine, Durham, NC, ²Duke University, Durham, NC, ³Exagen Inc., Vista, CA, ⁴Duke University, Chapel Hill, NC
Background/Purpose: HCQ levels reflect adherence and have been shown to correlate with SLE outcomes. However, HCQ levels have not been studied in the context of…
Abstract Number: 1227 • ACR Convergence 2021
Clinical Predictors of Response to Methotrexate in Patients with Rheumatoid Arthritis: A Machine Learning Approach Using Clinical Trial Data
Stephanie Duong¹, Cynthia Crowson², Elizabeth Atkinson¹, Arjun Athreya¹, John Davis¹, Eric Matteson³, Richard Weinshilboum¹, Liewei Wang¹ and Elena Myasoedova¹, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Eyota, MN, ³Mayo Clinic College of Medicine and Science, Rochester, MN
Background/Purpose: Methotrexate (MTX) is the preferred initial disease-modifying drug (DMARD) for rheumatoid arthritis (RA). However, up to 50% of patients respond inadequately to MTX. Clinically…
Abstract Number: 1334 • ACR Convergence 2021
How Does Gender Affect Secukinumab Treatment Outcomes and Retention Rates in Patients with Psoriatic Arthritis? – Real World Data from a German Observational Study
Uta Kiltz¹, Jan Brandt-Jrgens², Peter Kästner³, Elke Riechers⁴, Daniel Peterlik⁵ and Hans-Peter Tony⁶, ¹Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany, ²Rheumatologische Schwerpunktpraxis, Berlin, Germany, ³Ambulantes Rheumazentrum Erfurt, Erfurt, Germany, ⁴Department for Rheumatology and Immunology, Hannover Medical University, Hannover, ⁵Novartis Pharma GmbH, Nürnberg, Germany, ⁶Universitätsklinikum Würzburg, Wuerzburg, Germany
Background/Purpose: Gender disparities in PsA can affect natural course of disease, clinical presentation and response to medication1. The German non-interventional study AQUILA provides real-world data…
Abstract Number: 1703 • ACR Convergence 2021
AP1189: A Novel Oral Biased Melanocortin Agonist with Anti-inflammatory and Pro-resolving Effect for the Treatment of Rheumatoid Arthritis
Thomas Jonassen¹, Thierry Duvauchelle¹, Birgitte Telmer², Irene Sandholdt², Thomas Boesen¹ and Ellen-Margrethe Hauge³, ¹SynAct Pharma, Holte, Denmark, ²CroxxMed, Hørsholm, Denmark, ³Aarhus University Hospital, Aarhus, Denmark
Background/Purpose: Melanocortin (MC) type 1 and type 3 receptor stimulation is associated with anti-inflammation and promotion of inflammatory resolution. AP1189 is a biased MC type…
Abstract Number: 1893 • ACR Convergence 2021
“From Where I Stand”: Using Multiple Anchors Yields Different Benchmarks for Meaningful Improvement and Worsening in the Rheumatoid Arthritis Flare Questionnaire (RA-FQ)
Susan Bartlett¹, Vivian Bykerk², Orit Schieir³, Marie-France Valois¹, Louis Bessette⁴, Gilles Boire⁵, Glen Hazlewood⁶, Carol Hitchon⁷, Edward Keystone⁸, Janet Pope⁹, Diane Tin¹⁰, Carter Thorne¹¹, Clifton Bingham¹² and CATCH Investigators¹³, ¹McGill University, Montréal, QC, Canada, ²Hospital for Special Surgery, New York, NY, ³Canadian Early Arthritis Cohort Study, Montréal, QC, Canada, ⁴Centre de l'Ostoporose et de Rhumatologie de Qubec, Québec City, QC, Canada, ⁵Universite de Sherbrooke, Sherbrooke, QC, Canada, ⁶University of Calgary, Calgary, AB, Canada, ⁷University of Manitoba, Winnipeg, MB, Canada, ⁸Keystone Consulting Enterprises Inc., Toronto, ON, Canada, ⁹University of Western Ontario, London, ON, Canada, ¹⁰The Arthritis Program Research Group, Newmarket, ON, Canada, ¹¹Southlake Regional Health Centre, Newmarket, ON, Canada, ¹²Johns Hopkins University, Baltimore, MD, ¹³Canadian Early Arthritis Cohort Investigators, Toronto, ON, Canada
Background/Purpose: The RA-FQ is a patient-reported measure of current disease activity in RA that can be used to identify disease flares. The RA-FQ queries pain,…
Abstract Number: 0105 • ACR Convergence 2021
Most Patients with Spondylitis Accept COVID-19 Vaccination and Few Experience Disease Exacerbation After Immunization
Rachel Higgins¹, Hedley Hamilton², Michael Weisman³, John Reveille⁴, Kimbery Ogle¹, Cassie Shafer⁵, Elin Aslanyan⁵, Richard Howard⁵, Dongseok Choi¹, James T. Rosenbaum⁶ and Kevin Winthrop¹, ¹Oregon Health & Science University, Portland, OR, ²Any-3 Ltd, London, United Kingdom, ³Adjunct Professor of Medicine, Stanford University; Distinguished Professor of Medicine Emeritus, David Geffen School of Medicine at UCLA, Los Angeles, CA, ⁴Division of Rheumatology, The University of Texas Health Science Center at Houston, Houston, TX, ⁵Spondylitis Association of America, Encino, CA, ⁶Departments of Ophthalmology, Medicine, and Cell Biology, Oregon Health & Sciences University and Chair Emeritus, Legacy Devers Eye Institute, Portland, OR
Background/Purpose: Patients with rheumatic and musculoskeletal diseases (RMDs) remain at an increased risk of morbidity and mortality from vaccine preventable infections, often as a result…
Abstract Number: 0362 • ACR Convergence 2021
Achievement of Stringent Thresholds of Disease Control Is Associated with Reduced Burden on Work and Household Productivity in Patients with Axial Spondyloarthritis
Martin Rudwaleit¹, Pedro Machado², Lianne Gensler³, Vanessa Taieb⁴, Natasha de Peyrecave⁵, Bengt Hoepken⁶ and Désirée van der Heijde⁷, ¹University of Bielefeld, Klinikum Bielefeld, Bielefeld, Germany, ²Centre for Rheumatology & Department of Neuromuscular Diseases, University College London, London, United Kingdom, ³Department of Rheumatology, University of California San Francisco, San Francisco, CA, ⁴UCB Pharma, Slough, United Kingdom, ⁵UCB Pharma, Brussels, Belgium, ⁶UCB Pharma, Monheim am Rhein, Germany, ⁷Department of Rheumatology, Leiden University Medical Center, Meerssen, Netherlands
Background/Purpose: Axial spondyloarthritis (axSpA) is associated with increased absence from work and reduced work productivity, which can impact employment status.1 TNF inhibitors such as certolizumab…
Abstract Number: 0760 • ACR Convergence 2021
The Performance of RA Disease Activity and Patient-Reported Outcomes in Rheumatoid Arthritis-Associated Interstitial Lung Disease in a Prospective Trial Using Pirfenidone in RA ILD (TRAIL1)
Paul Dellaripa¹, Tracy Doyle², Sonye Danoff³, Hillary Goldberg¹, Martin Kolb⁴, Daniel Chambers⁵, Felix Woodhead⁶, Cathy Spino⁷, Ivan Rosas⁸ and Joshua Solomon⁹, ¹Brigham and Women's, Boston, MA, ²Brigham and Women's Hospital, West Roxbury, MA, ³Johns Hopkins Medicine, Baltimore, MD, ⁴McMaster University, Hamilton, ON, Canada, ⁵University of Queensland, Brisbane St Lucia, Australia, ⁶University of Leicester, Leicester, United Kingdom, ⁷University of Michigan, Ann Arbor, MI, ⁸Baylor College of Medicine, Houston, TX, ⁹National Jewish Health, Denver, CO
Background/Purpose: Both rheumatoid arthritis (RA) and idiopathic pulmonary fibrosis (IPF) have established measures of disease severity and patient reported outcomes (PROs) that measure health-related quality…
Abstract Number: 0878 • ACR Convergence 2021
Investigating the Neutrophil to Lymphocyte Ratio as a Marker of SLE Disease Activity, Health-Related Quality of Life and Depression
Eleni Papachristodoulou¹, Loukas Kakoullis¹, Savvas Psarelis², Victor Hajiroussos³, Costas Christophi⁴ and Konstantinos Parperis¹, ¹University of Cyprus Medical School, Nicosia, Cyprus, ²Nicosia General Hospital/University of Cyprus Medical Schooll, Nicosia, Cyprus, ³Ygia Polyclinic Hospital, Limassol, Cyprus, ⁴Cyprus University of Technology, Limassol, Cyprus
Background/Purpose: The need for readily available markers of SLE activity has led to the evaluation of laboratory parameters, such as the neutrophil to lymphocyte ratio…
Abstract Number: 1231 • ACR Convergence 2021
Consistent Impact of Autoantibody Enrichment Across All ACR Core Measures in Early Rheumatoid Arthritis Treated with Abatacept: Data from a Large Pooled Analysis of 4 Randomized Controlled Trials
Philip Conaghan¹, Sang Hee Park², Mirko Fillbrunn³, Karissa Lozenski², Vadim Khaychuk², Kaleb Michaud⁴, Elyse Swallow³, Henry Lane³, Ha Nguyen³ and Janet Pope⁵, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ²Bristol Myers Squibb, Princeton, NJ, ³Analysis Group, Inc., Boston, MA, ⁴University of Nebraska Medical Center, Omaha, NE, ⁵University of Western Ontario, London, ON, Canada
Background/Purpose: Biomarkers play an important role in RA and can help guide treatment decisions. Previous studies have suggested differential treatment efficacy of abatacept (ABA) in…
Abstract Number: 1338 • ACR Convergence 2021
Bimekizumab in Patients with Psoriatic Arthritis: 3-Year Results for Overall and Tumor Necrosis Factor Inhibitor (TNFi)-Naïve Populations from a Phase 2b Open-Label Extension Study
Philip Mease¹, Atul Deodhar², Joseph Merola³, Iain McInnes⁴, Deepak Assudani⁵, Rajan Bajracharya⁵, Jason Coarse⁶, Barbara Ink⁷ and Georg Schett⁸, ¹Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, ²Oregon Health & Science University, Portland, OR, ³Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁴University of Glasgow, School of Medicine, Glasgow, Scotland, United Kingdom, ⁵UCB Pharma, Slough, United Kingdom, ⁶UCB Pharma, Raleigh, NC, ⁷UCB Celltech, Slough, UK, Slough, United Kingdom, ⁸Universitätsklinikum Erlangen, Department of Internal Medicine 3 – Rheumatology and Immunology, Erlangen, Germany, Erlangen, Germany
Background/Purpose: Bimekizumab (BKZ) is a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)-17F and IL-17A, and has demonstrated clinical improvements in joint and skin outcomes…
Abstract Number: 1704 • ACR Convergence 2021
Tofacitinib in Rheumatoid Arthritis: Is There a Correlation Between a Rapid Analgesic Effect and a Decrease in Activity After 3 and 6 Months?
Elena Pogozheva¹, Andrey Karateev¹, Evgeniy Nasonov¹, Alexander Lila¹, Vadim Mazurov², Rusanna Samigullina³, Diana Chakieva⁴, Anna Dadalova⁴, Anna Dyo⁴, Andrey Baranov⁵, Natalia Lapkina⁵, Ekaterina Kol’tsova⁶, Ivan Shchendrigin⁷, Tatyana Rasevich⁸, Antonina Davydova⁹, Irina Shafieva¹⁰, Inna Bashkova¹¹, Daria Bobrikova¹², Irina Kushnir¹³, Elena Kalinina¹⁴, Tatiana Sal’nikova¹⁵, Valentina Sorotskaya¹⁶, Irina Marusenko¹⁷, Olga Semagina¹⁸, Irina Vinogradova¹⁹, Diana Krechikova²⁰, Natalia Kiryukhina²¹, Irina Semizarova²², Dzhamilya Murtazalieva²³ and Marina Semchenkova²⁴, ¹V.A. Nasonova Reseach Institute of Rheumatology, Moscow, Russia, ²Mechnikov North-Western State Medical University, Saint Petersburg, Russia, ³Mechnikov North-Western State Medical University, St.Petersburg, Russia, ⁴Mechnikov North-Western State Medical University, St. Petersburg, Russia, ⁵Yaroslavl State Medical University, Yaroslavl, Russia, ⁶Scientific and Research Institute of Health Care Organization, Moscow, Russia, ⁷Stavropol Regional Clinical Hospital, Stavropol, Russia, ⁸Astrakhan Region Alexandro-Mariinsky Regional Clinical Hospital, Astrakhan, Russia, ⁹Regional Clinical Hospital №1 named. prof. S. V. Ochapovskogo, Krasnodar, Russia, ¹⁰Samara State Medical University of the Ministry of Health of the Russian Federation, Samara, Russia, ¹¹Advisory Polyclinic Chuvash State University named after I. N. Ulyanov, Cheboksary, Russia, ¹²Regional Clinical Hospital No. 1, Tyumen', Russia, ¹³Kemerovo regional clinical hospital, Kemerovo, Russia, ¹⁴Volgograd State Medical University, Volgograd, Russia, ¹⁵Regional Clinical Hospital, Tula, Russia, ¹⁶Tula State Medical University, Tula, Russia, ¹⁷Petrozavodsk State University, Petrozavodsk, Russia, ¹⁸Regional Clinical Hospital, Samara, Russia, ¹⁹Regional Clinical Hospital, Ulyanovsk, Russia, ²⁰Smolensk State Medical University, Smolensk, Russia, ²¹National Medical and Surgical Center named after N.I. Pirogov” of the Ministry of Healthcare of the Russian Federation, Moscow, Russia, ²²Regional Clinical Hospital, Krasnodar, Russia, ²³Moscow Clinical Scientific and Practical Centre named after Loginov A.S., Moscow, Russia, ²⁴Medical Clinical Centre, Smolensk, Russia
Background/Purpose: to investigate the correlation between the rapid analgesic effect of tofacitinib and a decrease in RA activity after 3 and 6 months.Methods: The study…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].